Back Home About Us

HIVandHepatitis.com 2017 Conference Coverage

Article listings by topic for HIVandHepatitis.com conference coverage in 2017, including the Conference on Retroviruses and Opportunistic Infections, EASL International Liver Congress, IAS Conference on HIV Science, and AASLD Liver Meeting.

alt

Read more:

Top 10 HIV and Hepatitis Stories of 2017

For our last issue, HIVandHepatitis.com reviews some the year's major HIV, viral hepatitis, and related news highlights. As we enter 2018, antiretroviral treatment for HIV is about as good as it can get, use of PrEP for HIV prevention is expanding rapidly, and most people can be cured of hepatitis C with 2 or 3 months of well-tolerated therapy. But these advances are still not reaching everyone who needs them. The search for a functional cure for HIV, better treatments for hepatitis B, and management of fatty liver disease remain major challenges for the year ahead.

alt

Read more:

BHIVA 2017: Despite Reassuring Data, We Can’t Yet Say U=U for Breastfeeding

While effective HIV treatment greatly reduces the risk of onward transmission during breastfeeding, it does not appear that the risk is zero, a leading pediatrician told the British HIV Association (BHIVA) conference last month in London last week.

alt

Read more:

A Message To Our Readers

As of the new year, HIVandHepatitis.com will be transferred to Smart + Strong, the publisher of POZ, Hep, Real Health, and the new Cancer Health magazines and websites. HIVandHepatitis.com will remain online as an archive for the near future but will not publish new content. HIVandHepatitis.com editor Liz Highleyman is now editor-in-chief of Cancer Health.

alt

Read more:

FDA Approves Juluca Dual Single-Tablet Regimen

On November 21, the U.S. Food and Drug Administration approved Juluca, a fixed-dose coformulation containing dolutegravir and rilpivirine, for the treatment of adults with HIV who have undetectable viral load on their current antiretroviral regimen. Juluca, a joint product of ViiV Healthcare and Janssen, is the first complete single-tablet regimen containing only 2 drugs.

alt

Read more:

HIV Cure Summit Hears About New Remission Case

The past year brought no major breakthroughs in the search for an HIV cure, but a growing understanding of how the virus hides in the body bring us closer to strategies for long-term remission, researchers and advocates said at the 2017 HIV Cure Summit in San Francisco.

alt

Read more:

EACS 2017: New European Guidelines Cover HIV, Hepatitis C, and Related Conditions

Everyone with HIV and hepatitis C virus (HCV) coinfection should receive direct-acting antiviral therapy for hepatitis C and should receive the same treatment regimens for hepatitis C as people with HCV monoinfection, new European guidelines issued at the 16th European AIDS Conference recommend.

alt

Read more:

San Francisco Getting to Zero Update Hears U=U Message

San Francisco continues to make progress in reducing new HIV infections and expanding access to early treatment, according to a World AIDS Day update on the city's Getting to Zero initiative, held on November 29, 2017.

alt

Read more:

EACS 2017: Fostemsavir Controls Viral Load in Half of People with Highly Drug-Resistant HIV

Fostemsavir, a new experimental attachment inhibitor, suppressed viral load in over half of participants with extensive drug resistance when added to a background regimen selected by resistance testing, Max Lataillade of ViiV Healthcare reported at the recent 16th European AIDS Conference in Milan.

alt

Read more: